HRX-0233

Biorbyt

HRX-0233

10

Research Use Only

98.00%

C24H21F2N5O3S

497.52

HRX-0233 is a small molecule inhibitor targeting MAP2K4. In vivo, HRX-0233 effectively reduces tumors in H358 KRASG12C mutant non-small cell lung cancer (NSCLC) without significant toxicity. This compound also prevents feedback activation of receptor tyrosine kinases (RTKs) when used as a monotherapy with the KRAS inhibitor Sotorasib, leading to more sustained and comprehensive inhibition of the MAPK signaling pathway. HRX-0233 holds potential for research in AR-negative prostate cancer, lung cancer, and colon cancer.

O=C(C1=CC=C(F)C(NS(=O)(=O)CCC)=C1F)C2=CNC3=NC=C(C=C32)C=4C=NC(=NC4)C5CC5

-20°C

12352200